|Dr. George E. Anastassov M.D., DDS, MBA||Chairman, CEO & Pres||955.62k||N/A||54|
|Mr. Lekhram Changoer||CTO & Director||818.2k||N/A||50|
|Dr. Philip A. Van Damme DMD, MD, Ph.D.||Chief Scientific Officer & Director||54k||N/A||64|
|Mr. Robert T. Malasek||CFO & Sec.||N/A||N/A||49|
AXIM Biotechnologies, Inc., a biotechnology company, focuses on the treatment of pain, spasticity, anxiety, and other medical disorders with the application of cannabinoids based products. It also focuses on the research, development, and production of pharmaceutical, nutraceutical, oral health, and cosmetic products, as well as procurement of genetically and nano-controlled active ingredients. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was founded in 2010 and is based in New York, New York.
AXIM Biotechnologies, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.